health
Daewoong Pharmaceutical Presents Baseline Characteristics of 104 Patients in Global Phase 2 Trial for IPF Drug Candidate 'Bersiporocin' at ERS 2026
104 IPF patients enrolled in US and South Korea as global Phase 2 trial progresses toward completion Study includes both antifibrotic-treated and untreated patients; top-line data expected in H1 2027 First-in-class PRS inhibitor being developed as a potential new therapeutic option for...
ONLY AVAILABLE IN PAID PLANS
Read Full ArticleShare this story
Up next
Related Stories
Overprescribing can take a toll on older peoples’ health and independence - here’s what can be done
The Conversation
Only 2pc can spot signs of common heart risk
New England Times
Victoria’s Dedicated Health Workforce Deliver Record Care
The National Tribune
New Program to Fast-Track Provincial Clinical Trials
Mirage News
Oral HRT link with blood clots
Pharmacy Daily